OSE receives grant from French National Research Agency

Company is to validate new targets linked to myeloid cells and identify innovative new immunotherapies in oncology
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
NANTES, France—OSE Immunotherapeutics announced recently that its DC-TARGET project has been selected by the French National Research Agency (ANR) to be awarded a grant up to €800,000 following the “AAPG 2019” call for proposals assessment process.
 
The aim of this program is to identify new targets of interest expressed by myeloid cells (tumor associated macrophages, myeloid-derived suppressive cells, dendritic cells). These suppressive immune cells play a major role in both tumor immune escape and in their invasive process. In order to discover new targets of therapeutic interest in the tumor microenvironment, the role of each cell will be characterized in depth by single cell RNAseq and gene editing.
 
Once the targets identified and clinically validated, OSE Immunotherapeutics will focus on translation of the research study findings through the development of specific monoclonal antibodies that are able to block the deleterious targets identified.
 
In particular, this immuno-oncology research program will explore tissues from triple negative breast cancer, a cancer with a high risk of progression.
 
“This new collaboration with the Léon Bérard cancer research center, a leader in modern oncology treatments combining translational and immunological research platforms, is focused on an aggressive breast cancer with a strong need for medical innovation. OSE is already strongly involved clinically in the field of myeloid cell-based therapies for cancers,” said Alexis Peyroles, CEO of OSE Immunotherapeutics.

Related Topics

Published In

Volume 15 - Issue 8 | August 2019

August 2019

August 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue